Nandu Deorkar, Ph.D., MBA, senior vice president, research & development, biopharma production; and George Marquez, vice president, operations, Avantor, discuss advancing clinical trials manufacturing from pilot to production in our latest EPM issue.
The EMPACT-MI phase III clinical trial showed a 10% relative risk reduction in the primary composite endpoint of time to first hospitalisation due to heart failure or all-cause mortality for empagliflozin versus placebo.
Paul Knight, Managing Director of CME Automation Systems analyses one of the biggest challenges facing the life sciences industry: how to implement automated ‘just-in-time’ clinical supply chains.
Corteria Pharmaceuticals have announced the initiation of its Phase 1 study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure.
It’s long been a concern for scientists and regulators that drugs are intended for use by anyone but are predominantly tested on one group – white men. Richard Staines reports on how this could change.
In this article, Jeff Livick, Director of Business Development at Sharp Services will explore the trends from 2023, how they will shape the industry in the coming year, and predictions for 2024.
John Cardone, Marketing Manager, Custom Antibodies, Bio-Rad Laboratories explores Monitoring Antibody Drug Safety and Efficacy in Preclinical and Clinical Development in our latest EPM insight.
Stephan Ohnmacht and Werner Engelbrecht explore EMA’s vision of a single source of truth for clinical trial information forces a major shift in how companies collect and store trial data and documents.
